Renpress
Renpress Uses, Dosage, Side Effects, Food Interaction and all others data.
Renpress is an ACE inhibitor antihypertensive drug used to treat hypertension. Renpress is converted to the active spiraprilat after administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.
Renpress is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, spirapril decreases angiotensin II which is a vasoconstrictor and inducer of aldosterone. So by inhibiting the enzymes, aldosterone secreation is decreased (so less sodium is reabsorbed) and there is a decrease in vasoconstriction. Combined, this leades to a decrease in blood pressure.
Trade Name | Renpress |
Generic | Spirapril |
Spirapril Other Names | Espirapril, Spirapril, Spiraprilum |
Type | |
Formula | C22H30N2O5S2 |
Weight | Average: 466.614 Monoisotopic: 466.15961346 |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | Czech Republic, Slovakia |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Renpress is an ACE inhibitor class drug used to treat hypertension.
How Renpress works
Renpressat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Renpressat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Food Interaction
- Avoid hypertensive herbs (e.g. bayberry, blue cohosh, cayenne, ephedra, and licorice).
- Avoid potassium-containing products. Potassium products increase the risk of hyperkalemia.
- Limit salt intake. Salt may attenuate the antihypertensive effect.
Elimination Route
Bioavailability is 50% following oral administration.
Half Life
30 to 35 hours
Innovators Monograph
You find simplified version here Renpress